4405

Unified Proton and Fluorine Imaging of Small and Low Spin Density Samples at a Human Whole-Body 7 T MRI

Christian Bruns¹, Tim Herrmann¹, Markus Plaumann¹, Chang-Hyun Oh², Chulhyun Lee ³, Suchit Kumar⁴, and Johannes Bernarding¹

¹Department for Biometrics und Medical Informatics, Otto-von-Guericke University, Magdeburg, Germany, ²Department of Electronics and Information Engineering, and Korea Artificial Organ Center, Korea University, Seoul, Korea, Republic of, ³Bioimaging Research Team, Korea Basic Science Institute, Ochang, Korea, Republic of, ⁴Department of Biomicrosystem Technology and Korea Artificial Organ Center, Korea University, Seoul, Korea, Republic of

Synopsis

In order to provide a system, which allows imaging of ¹⁹F MR contrast agents, an in-house-built ¹⁹F/¹H transmit/receive system for 7 T was successfully tested in a human whole-body 7 T MRI system. This system enables the measurement of concentrations of 1.85 mM. For this approach we used a ¹⁹F tuned coil which provided still enough signal gain at the proton frequency to allow ¹H imaging for comparison. This showed the possibility of using ¹⁹F as contrast agents with a quite simple coil design in comparison to other dual tuned approaches.

Introduction

The number of fluorinated substrates used as pharmaceutical drugs has increased considerably during the last years¹. For medical chemistry and therapy, fluorinated substrates are of high interest, because of the very low natural abundance of fluorine in living organisms leading to background-free ¹⁹F images. Furthermore, the high MR sensitivity predestines fluorine for ¹⁹F MRS and MRI examinations as a part of contrast agents, e.g. for metabolism studies of pharmaceuticals by using MR techniques^{2,3}. However, to date, studies of ¹⁹F MRI at 7 T are rare due to the lack of existing coils⁴. Therefore, we have developed and successfully tested in-house-built ¹⁹F/¹H transmit/receive system for 7 T imaging in a proof of principle study. In order to use such a system for detection of contrast agents it is important to be able to detect small volumes as well as small concentrations of the investigated substrates. To exploit the potential for fast imaging, for short TE-substrates containing low concentrations of ¹⁹F such as solid TEFLON cases, and for optimizing SNR ultra-short TE sequences were adapted to ¹⁹F imaging.

Methods

Measurements were performed with a human whole-body 7 T MRI system (Siemens, Erlangen, Germany). The transmit/receive coil and the casing were designed and build in-house (Fig. 1). The 4 array-elements of the coil were capacitively decoupled and matched to 279.5 MHz, which is the Larmor frequency of ¹⁹F at 7 T. The coil elements and the transmit-box were constructed to optimize the ¹⁹F-signal at a still sufficiently high gain of the ¹H-signal for imaging and shimming. The volume coil had an inner diameter of 6.7 cm. The study used different phantoms: (i) a pure 2,2,2-trifluoroethanol (TFE, C₂H₃F₃O) bottle phantom of 4 cm diameter and (ii) 15 ml falcon tubes with different concentrations of TFE dissolved in H₂O (distilled water) between 926.9 mM and 1.85 mM (Fig. 2). For comparison between the obtained ¹H to ¹⁹F imaging two different sequences were used: UTE (Ultrashort Time of Echo) and FLASH (Fast Low Angle Shot) sequences for imaging (for sequence parameters see figure captions). Both standard ¹H sequences were adapted for ¹⁹F.

Results and discussion

The sensitivity of the coil-transmit-box unit provided sufficiently high signal intensities both at ¹⁹F and ¹H which enabled shimming at ¹H and imaging at ¹H and ¹⁹F frequencies even in case of 100% trifluoroethanol phantom. The phantoms showed good SNR and image homogeneity (Fig. 3 and 4) in the ¹H and the ¹⁹F images. This demonstrates, that imaging for ¹⁹F and ¹H substrates at a 7 T human scanner is feasible. Except for the volume of the imaged object the spin density and substrate concentration plays an important role when using ¹⁹F as a molecular marker substance or contrast agent. In our case we could image concentrations down to 1.85 mM, which is under the sensitivity required for contrast agents⁵ (Fig. 4). Thus, the coil architecture and the increased signal at 7 T show, that small amounts of ¹⁹F-labeled substances are well detectable potentially enabling the therapeutic monitoring of ¹⁹F drugs or using ¹⁹F-labeld substances as new contrast agents. The current system can be optimized in decoupling and contacts, which will lead to an even better sensitivity. This means that the diameter of the coil can be extended to a size of a head, which is important for further studies with ¹⁹F drugs.

So far, we have only used the ¹H signal for shimming; an optimization of the ¹⁹F shimming is currently under investigation.

Using the same coil elements for simultaneous ¹⁹F and ¹H measurements represents an advantage compared to complex dual tuned coils as no additional manipulation is necessary when switching between ¹H and ¹⁹F. Besides this, the results show that the signal from ¹H is still high enough to enable anatomic imaging (Fig. 3) allowing to use both image information, e.g., to depict ¹⁹F information on standard anatomy.

This study used trifluoroethanol as a ¹⁹F substrate due to its solubility in water. However, other ¹⁹F substances can be similarly used. Other non-toxic substances are now under investigation.

Conclusion

The results show that our concept of a phased-array coil with sufficiently broad frequency range allows for ¹H and ¹⁹F imaging of fluorinated substances at a 7 T whole-body system designed for use of human in-vivo examination even if spin density are low. As 7 T will soon be available for clinical diagnostics this may provide new possibilities to monitor fluorinated drugs used in tumor therapy or treatment of psychiatric diseases.

Acknowledgements

This work was supported by the BMBF Project 01DR12111: "EDUHF-LAB MRI" - A German-Korean laboratory for training, development and research in ultrahigh field whole-body MRI-technology.

References

1. Wang J, Sánchez-Roselló M, Aceña JL et al. Fluorine in pharmaceutical industry: fluorine-containing drugs introduced to the market in the last decade (2001-2011). Chem. Rev. 2014; 114: 2432–250.

2. Ruiz-Cabello J, Barnett BP, Bottomley PA et al. Fluorine (¹⁹F) MRS and MRI in biomedicine. NMR Biomed. 2011; 24(2): 114-129.

3. Jiang Z-X, Liu X, Jeong E-K et al. Symmetry-guided Design and Fluorous Synthesis of A Stable and Rapidly Excreted Imaging Tracer for ¹⁹F MRI. Angew. Chem. Int. Ed. 2009; 48: 4755–4758.

4. Amiri H, Srinivas M, Veltien A et al. Cell tracking using ¹⁹F magnetic resonance imaging: Technical aspects and challenges towards clinical applications. Eur. Radiol. 2015; 25: 726–735.

5. Kenny GD, Shaw KP, Sivachelvam S et al. A bisphosphonate for ¹⁹F-magnetic resonance imaging. J. Fluor. Chem. 2016; 148: 58-64.

Figures



Figure 1: 4-element-phased array coil. The coil was designed and printed in-house.



Figure 2: Phantoms used in the study. Left: Simple bottle phantom (diameter of 4 cm) filled with pure trifluoroethanol ($C_2H_3F_3O$) for testing the coil design; right: 15 ml falcon tubes with different concentrations of trifluoroethanol dissolved in H₂O (distilled water).



Figure 3: Comparable imaging of the pure trifluoroethanol ($C_2H_3F_3O$) phantom (Fig. 2) with a FLASH sequence. Left: ¹⁹F (TE=4.8 ms, TR=4000 ms, 1.5 mm x 1.5 mm x 4 mm); right: 1H (TE=4.8 ms, TR=200 ms, 1.2 mm x 1.2 mm x 4 mm).



cds.ismrm.org/protected/17MProceedings/PDFfiles/4405.html

Figure 4: ¹⁹F imaging (UTE sequence, TE=8 ms, TR=200 ms, Voxelsize: 2.3 mm x 2.3 mm x 3mm) of 15 ml falcon tubes with different concentrations of trifluoroethanol: a) 926.9 mM, b) 231.7 mM, c) 463.4 mM, and d) 46.3 mM.

Proc. Intl. Soc. Mag. Reson. Med. 25 (2017) 4405